India's leadership in cost-efficient generics is unchallenged: Sanjiv Kaul

Price erosion has been in excess of 15 per cent last year and will perhaps be at similar levels this year due to sales channel consolidation, says Kaul

ChrysCapital invested $20 million in dermatology product maker Curatio Healthcare early this week, making it the 10th investment of the homegrown PE firm into Indian Pharma. Sanjiv Kaul, partner at the PE firm, has spent over 40 years in Indian pharma, including a 27-year stint in various leadership roles at erstwhile Ranbaxy Laboratories. Kaul, in an interview with Abhineet Kumar, talks about investment potential of Indian pharma. Edited excerpts:
 
Which are the key areas of interests in pharma for PE investments?
 
The formulations segment has traditionally been a thrust area for PE investments in India with emphasis